Table III.
Subgroup analyses in patients with chemotherapy-bevacizumab vs. chemotherapy alone from the matched dataset.
| Subgroups | Median PFS (months) | Median OS (months) | HR (95% CI) | P-value |
|---|---|---|---|---|
| Male sex | 5.6 vs. 2.0 | – | 0.24 (0.10–0.54) | <0.0001 |
| Current/former smokers | 4.3 vs. 2.2 | – | 0.32 (0.13–0.78) | 0.008 |
| Adenocarcinoma | 3.9 vs. 2.2 | – | 0.59 (0.35–0.99) | 0.037 |
| EGFR wild-type/unknown | 6.3 vs. 2.9 | – | 0.26 (0.12–0.58) | <0.0001 |
| Prior regimens ≤3 | 3.9 vs. 2.2 | – | 0.55 (0.30–0.99) | 0.038 |
| Gemcitabine | 4.3 vs. 2.5 | – | 0.55 (0.30–1.01) | |
| Prior regimens >3 | – | 14.0 vs. 5.4 | 0.29 (0.09–0.92) | 0.025 |
| Docetaxel | – | 14.0 vs. 8.0 | 0.01 (0.00–37.70) |
EGFR, epidermal growth factor receptor; PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval.